Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19799
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRussell, Nicholas-
dc.contributor.authorGrossmann, Mathis-
dc.date2018-11-13-
dc.date.accessioned2018-11-26T00:51:06Z-
dc.date.available2018-11-26T00:51:06Z-
dc.date.issued2021-
dc.identifier.citationUrologic Oncology 2021; 39(10): 704-712en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19799-
dc.description.abstractAndrogen deprivation therapy (ADT) is commonly given to men with prostate cancer. Both its benefits as well as its adverse effects are a direct consequence of sex steroid withdrawal. While ADT improves oncologic outcomes in appropriately selected men, it is associated with adverse effects, including accelerated bone loss leading to increased fracture risk, and with metabolically unfavorable body composition changes that predispose to diabetes and may increase cardiovascular risk. In this review, we will describe the pathophysiology behind these ADT-associated adverse effects, and discuss the clinical evidence guiding clinical assessment and management. A proactive approach is important to minimize ADT-associated adverse sequelae, so that the benefit-risk ratio of this treatment is optimized.en_US
dc.language.isoeng-
dc.subject25(OH)Den_US
dc.subject25-hydroxy vitamin Den_US
dc.subjectADTen_US
dc.subjectARen_US
dc.subjectARKOen_US
dc.subjectAndrogen deprivation therapyen_US
dc.subjectBMDen_US
dc.subjectBPen_US
dc.subjectCRPCen_US
dc.subjectCaPen_US
dc.subjectDBPen_US
dc.subjectDXAen_US
dc.subjectDiabetesen_US
dc.subjectGnRHen_US
dc.subjectHDL-Cen_US
dc.subjectHR-PQCTen_US
dc.subjectLBMen_US
dc.subjectLDL-Cen_US
dc.subjectOsteoporosisen_US
dc.subjectProstate canceren_US
dc.subjectRCTen_US
dc.subjectSBPen_US
dc.subjectTCen_US
dc.subjectTGen_US
dc.subjectandrogen deprivation therapyen_US
dc.subjectandrogen receptoren_US
dc.subjectandrogen receptor knockouten_US
dc.subjectblood pressureen_US
dc.subjectbone mineral densityen_US
dc.subjectcastrate-resistant Prostate canceren_US
dc.subjectdiastolic blood pressureen_US
dc.subjectdual energy X-ray absorptiometryen_US
dc.subjectgonadotrophin-releasing hormoneen_US
dc.subjecthigh density lipoprotein cholesterolen_US
dc.subjecthigh resolution-peripheral quantitative computed tomographyen_US
dc.subjectlean body massen_US
dc.subjectlow density lipoprotein cholesterolen_US
dc.subjectProstate canceren_US
dc.subjectrandomized controlled trialen_US
dc.subjectsystolic blood pressureen_US
dc.subjecttotal cholesterolen_US
dc.subjecttriglyceridesen_US
dc.titleManagement of bone and metabolic effects of androgen deprivation therapy.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleUrologic Oncologyen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.doi10.1016/j.urolonc.2018.10.007en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-8261-3457en_US
dc.identifier.pubmedid30446463-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherGrossmann, Mathis
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.